In breast cancer, tumors harboring PIK3CA mutations are often resistant to HER2-based therapy [66,67,68], and are less likely to achieve pathologic complete response to anti-HER2 treatments [69,70]. This evidence concerns the gene PIK3CA and breast cancer.